StromaCare, a French biotechnology company specialising in the development of cancer immunotherapies through stroma modulation, today announces the appointment of Georges Rawadi as chief executive officer (CEO).
StromaCare focuses on the tumoural stroma as a novel approach to developing first-in-class therapies for fighting aggressive and resistant cancers.
The tumoural stroma is a complex ecosystem surrounding the tumour, which can include blood vessels, immune cells and fibroblasts.
It plays an important role in the initiation and progression of cancers.
The stroma can represent up to 80% of the tumoural volume and acts as a barrier, preventing the immune system and therapeutics from accessing tumour cells.
StromaCare’s lead drug candidate, a monoclonal antibody, has demonstrated strong efficacy in preclinical studies and a favourable safety profile.
Mr. Rawadi’s objectives include raising funds and building partnerships to support StromaCare’s lead product development towards clinical trials and continuing to develop the pipeline.
“I am very enthusiastic about Georges joining StromaCare as CEO,” said Philippe Archinard, president of the strategic committee at StromaCare. “His profound expertise in the biotechnology sector will facilitate StromaCare's transition from a preclinical to a clinical stage company and will shape the company to meet the challenges related to its growth. I, along with the board, wish him every success in his new role.”
Mr. Rawadi brings over 20 years of extensive experience in the pharma and biotech industry, having served in various key roles.
Notable among his achievements are his positions as CEO and board member at Celyad Oncology (Belgium - Euronext listed company) and Ysopia Bioscience (France). Additionally, Georges has held significant roles as chief of biotech studio development at EureKare (France), vice-president BD & IP at Celyad Oncology and vice-president business development at Cellectis (France - Nasdaq and Euronext listed company).
